ILZE MUNGOVAN, FNP-C
Family Nurse Practitioner · THOUSAND OAKS, CA
Individual Active NPI 1952181596
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,317 | 818,611 | $31,417,617 | $15,644,113 | $12,437,472 |
| 2023 | 452 | 101,275 | $5,851,544 | $2,923,474 | $2,329,569 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 190,570 | $1 | $1 |
| J1306 | Injection, inclisiran, 1 mg | 174,513 | $12 | $10 |
| J0897 | Injection, denosumab, 1 mg | 67,080 | $26 | $20 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 52,290 | $11 | $9 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 36,330 | $18 | $14 |
| J2182 | Injection, mepolizumab, 1 mg | 27,900 | $30 | $24 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 27,900 | $22 | $17 |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 27,340 | $48 | $38 |
| J2350 | Injection, ocrelizumab, 1 mg | 20,700 | $59 | $47 |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 17,000 | $18 | $14 |
| J3245 | Injection, tildrakizumab, 1 mg | 10,500 | $135 | $107 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 7,975 | $43 | $34 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | 95027315 | CA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in California
- NPI 1467216333
- NPI 1962163881
- NPI 1316550452
- NPI 1639824287
- NPI 1063096048
- NPI 1053174243
- NPI 1356119457
- NPI 1447968177
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.